Donate to AGSD

Thank you for your support!

Become a Member

Access to scholarships, events, and more!

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene
Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)